NovoNordisk NASH Study: Studying the Effects of Semaglutide in Patients with NASH and Fibrosis Stage 3

Clinical Trial Title

The Essence Study: Investigating the effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

Contact Information

Clinical Trial Protocol Description:

The Essence Study is investigating the effect of semaglutide compared to placebo in subjects with non-alcoholic steatohepatitis (NASH) and Stage 3 fibrosis. This is an injectable drug administered every week.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have histological evidence of fibrosis stage 3 based on a liver biopsy
  • Have a histological NAS score greater than or equal to 4 
  • Not have documented causes of chronic liver disease other than non-alcoholic fatty liver disease
  • Not have a HbA1c greater than 9.5% at screening.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Sujit Janardhan

Contact Information

Diana Goldman

Clinical Trial Location

Rush University Medical Center

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more